keyword
MENU ▼
Read by QxMD icon Read
search

Tardive

keyword
https://www.readbyqxmd.com/read/29352477/benzodiazepines-for-antipsychotic-induced-tardive-dyskinesia
#1
REVIEW
Hanna Bergman, Paranthaman S Bhoopathi, Karla Soares-Weiser
BACKGROUND: Tardive dyskinesia (TD) is a disfiguring movement disorder, often of the orofacial region, frequently caused by using antipsychotic drugs. A wide range of strategies have been used to help manage TD, and for those who are unable to have their antipsychotic medication stopped or substantially changed, the benzodiazepine group of drugs have been suggested as a useful adjunctive treatment. However, benzodiazepines are very addictive. OBJECTIVES: To determine the effects of benzodiazepines for antipsychotic-induced tardive dyskinesia in people with schizophrenia, schizoaffective disorder, or other chronic mental illnesses...
January 20, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29345877/comparing-treatments-for-tardive-dyskinesia
#2
Leslie L Citrome
Many treatment interventions for tardive dyskinesia have been studied, but some have better evidence than others. Read this CME activity to get an expert's perspectives on the evidence for older and newer treatments so that you can minimize abnormal movements in your patients.
November 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/29345876/assessing-patients-for-tardive-dyskinesia
#3
John M Kane
Do you regularly screen for tardive dyskinesia in at-risk patients? Explore this CME activity by a well-known expert for information on rating scales for screening, available diagnostic criteria, assessment tips, and monitoring recommendations.
November 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/29345874/epidemiology-and-prevention-of-tardive-dyskinesia
#4
Christoph U Correll
What risk factors suggest that patients are more likely to develop tardive dyskinesia (TD)? Can TD symptoms be prevented? Read this CME activity to learn about the prevalence, epidemiology, and prevention of these abnormal movements from an expert.
November 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/29342497/non-antipsychotic-catecholaminergic-drugs-for-antipsychotic-induced-tardive-dyskinesia
#5
REVIEW
Hany G El-Sayeh, John Rathbone, Karla Soares-Weiser, Hanna Bergman
BACKGROUND: Tardive dyskinesia (TD) is a disabling movement disorder associated with the prolonged use of antipsychotic medication. Several strategies have been examined in the treatment of TD. Currently, however, there is no clear evidence of the effectiveness of these drugs in TD and they have been associated with many side effects. One particular strategy would be to use pharmaceutical agents which are known to influence the catecholaminergic system at various junctures. OBJECTIVES: 1...
January 18, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29341821/deuterium-tetrabenazine-for-tardive-dyskinesia
#6
Michael A Cummings, George J Proctor, Stephen M Stahl
Tardive dyskinesia remains a significant, potentially stigmatizing or crippling adverse effect for any patient treated with an antipsychotic medication. While second- and third-generation antipsychotics have exhibited lower annual incidence rates for tardive dyskinesia than classic or first-generation agents, 3.9% versus 5.5%, the estimated incidence rate is only modestly lower. When coupled with the fact that second- and third-generation antipsychotic medications have come to be employed in treating a wider range of disorders (e...
January 2018: Clinical Schizophrenia & related Psychoses
https://www.readbyqxmd.com/read/29341071/anticholinergic-medication-for-antipsychotic-induced-tardive-dyskinesia
#7
REVIEW
Hanna Bergman, Karla Soares-Weiser
BACKGROUND: Antipsychotic (neuroleptic) medication is used extensively to treat people with serious mental illnesses. However, it is associated with a wide range of adverse effects, including movement disorders. Because of this, many people treated with antipsychotic medication also receive anticholinergic drugs in order to reduce some of the associated movement side-effects. However, there is also a suggestion from animal experiments that the chronic administration of anticholinergics could cause tardive dyskinesia...
January 17, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29341067/vitamin-e-for-antipsychotic-induced-tardive-dyskinesia
#8
REVIEW
Karla Soares-Weiser, Nicola Maayan, Hanna Bergman
BACKGROUND: Antipsychotic (neuroleptic) medication is used extensively to treat people with chronic mental illnesses. Its use, however, is associated with adverse effects, including movement disorders such as tardive dyskinesia (TD) - a problem often seen as repetitive involuntary movements around the mouth and face. Vitamin E has been proposed as a treatment to prevent or decrease TD. OBJECTIVES: The primary objective was to determine the clinical effects of vitamin E in people with schizophrenia or other chronic mental illness who had developed antipsychotic-induced TD...
January 17, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29338466/valbenazine-as-the-first-and-only-approved-treatment-for-adults-with-tardive-dyskinesia
#9
Harini Sarva, Claire Henchcliffe
Valbenazine is a selective VMAT2 inhibitor that the FDA approved in April 2017 for the specific treatment of tardive dyskinesia (TD), a movement disorder commonly caused by dopamine blocking agents. Valbenazine acts to decrease dopamine release, reducing excessive movement found in TD. Areas covered: This drug profile reviews the development of valbenazine and the clinical trials that led to its approval as the first treatment specific to TD. The literature search was performed with the PubMed online database...
January 17, 2018: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/29338294/the-importance-of-clinical-observation-a-case-of-subtle-tardive-dyskinesia-with-paliperidone-palmitate
#10
Hisham Mrb Omer, Andrew D Thompson
No abstract text is available yet for this article.
January 1, 2018: Australian and New Zealand Journal of Psychiatry
https://www.readbyqxmd.com/read/29332075/patient-evaluation-and-selection-for-movement-disorders-surgery-the-changing-spectrum-of-indications
#11
Steffen Paschen, Günther Deuschl
This report summarizes the state-of-the-art and controversies around patient selection for deep brain stimulation (DBS) for various conditions. Parkinson's disease (PD): several class I studies have shown superiority of DBS over best medical treatment for advanced PD with fluctuations and further inclusion criteria. One class I study suggests that PD patients with early motor complications might gain more quality of life if operated within 3 years after the onset of fluctuations. The subthalamic nucleus (STN) is still the standard target...
2018: Progress in Neurological Surgery
https://www.readbyqxmd.com/read/29332008/leg-stereotypy-syndrome-phenomenology-and-prevalence
#12
Mitesh Lotia, Michele K York, Adriana M Strutt, Joseph Jankovic
OBJECTIVES: To describe the phenomenology and prevalence of leg stereotypy syndrome (LSS), characterised chiefly by repetitive, rhythmical, stereotypic leg movement, especially when sitting. METHODS: We sought to characterise LSS in two groups of subjects: (1) general population (GP) group, defined as individuals accompanying patients during their visits to Baylor College of Medicine Parkinson's Disease Center and Movement Disorders Clinic who are not genetically related to the patients; and (2) movement disorders (MD) group, composed of consecutive patients with diagnoses of restless legs syndrome, Parkinson's disease, Tourette syndrome and tardive dyskinesia...
January 13, 2018: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/29327098/-rare-tremor-syndromes
#13
REVIEW
J S Becktepe, F Goevert, G Deuschl
BACKGROUND: There is a group of uncommon sporadic tremor syndromes, which are only partially taken into account in the current classification of tremor. Their knowledge is of diagnostic and therapeutic relevance and they should be considered in the differential diagnosis of frequent tremor syndromes. OBJECTIVE: Differential diagnostics and treatment of uncommon tremor syndromes. METHOD: Literature search (PubMed, Google Scholar). RESULTS: Holmes tremor, myorhythmia, palatal tremor, limb-shaking transient ischemic attack (TIA), tardive tremor, neuropathic tremor, tremor induced by peripheral trauma and orthostatic tremor syndrome are described...
January 11, 2018: Der Nervenarzt
https://www.readbyqxmd.com/read/29324468/switching-antipsychotic-treatment-to-aripiprazole-in-psychotic-patients-with-neuroleptic-induced-tardive-dyskinesia-a-24-week-follow-up-study
#14
Chia-Hsiang Chan, Hung-Yu Chan, Yen-Ching Chen
Aripiprazole is a second-generation antipsychotics, acting as a partial dopamine D2 receptor agonist. Previous studies on aripiprazole for tardive dyskinesia (TD) treatment were limited and inconclusive. This study was aimed to examine the effectiveness of aripiprazole in psychotic patients with a pre-existing TD. This was an open-label 24-week prospective cohort study conducted in a public mental hospital in Northern Taiwan from January 2009 to February 2010.Psychotic patients were cross-titrated of prior antipsychotics with aripiprazole, and the severity of TD was assessed at baseline and at weeks 2, 4, 8, 12, 16, 20, and 24...
January 10, 2018: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29282344/-symptoms-and-pathophysiology-of-dyskinesias
#15
Masahiko Tomiyama
Symptomatic characteristics and recent advances in understanding the pathophysiology of tardive dyskinesias and levodopa-induced dyskinesias were reviewed. After the advent of atypical antipsychotics, tardive dyskinesias became less frequent, at least as observed during a short-term follow up. The dopamine supersensitivity hypothesis stating that blockade of dopamine D2 receptors by antipsychotics makes D2 receptors more sensitive to dopamine, has long been proposed. However, the true mechanisms remain to be determined...
December 2017: Brain and Nerve, Shinkei Kenkyū No Shinpo
https://www.readbyqxmd.com/read/29276353/a-cross-sectional-study-on-the-characteristics-of-tardive-dyskinesia-in-patients-with-chronic-schizophrenia
#16
Yanan Huang, Lizhen Pan, Fei Teng, Geying Wang, Chenhu Li, Lingjing Jin
Background: Tardive dyskinesia (TD) is an abnormal involuntary movement disorder caused by patients' long-term use of antipsychotic medication. It diminishes the social functioning of patients with mental disorders, thereby affecting their compliance with antipsychotic medication. The cause and nosogenesis of TD remains unclear; furthermore, because the presentation differs greatly among individuals it often goes undiagnosed or can be easily misdiagnosed. The present study aims to evaluate the abnormal movement patterns in patients with TD, and analyze the differences among different TD patterns, in order to seek effective methods of preventing, diagnosing and treating TD...
October 25, 2017: Shanghai Archives of Psychiatry
https://www.readbyqxmd.com/read/29249207/mechanism-of-action-of-vesicular-monoamine-transporter-2-vmat2-inhibitors-in-tardive-dyskinesia-reducing-dopamine-leads-to-less-go-and-more-stop-from-the-motor-striatum-for-robust-therapeutic-effects
#17
Stephen M Stahl
Tardive dyskinesia can now be successfully treated by inhibiting the vesicular monoamine transporter type 2 (VMAT2).
December 18, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/29246613/clinical-management-of-tardive-dyskinesia-five-steps-to-success
#18
REVIEW
Leslie Citrome
Tardive dyskinesia (TD) has long been thought to be a generally irreversible consequence of the use of dopamine receptor blocking agents. There is now an opportunity to successfully manage this condition with agents approved by the US Food and Drug Administration. This is important because TD has not been eliminated with the use of second-generation antipsychotics, and the expansion of antipsychotics to treat conditions other than schizophrenia has resulted in millions of additional individuals at risk for developing TD...
December 15, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29242310/approaches-to-neuromodulation-for-schizophrenia
#19
REVIEW
Judith M Gault, Rachel Davis, Nicola G Cascella, Elyn R Saks, Iluminada Corripio-Collado, William S Anderson, Ann Olincy, John A Thompson, Edith Pomarol-Clotet, Akira Sawa, Zafiris J Daskalakis, Nir Lipsman, Aviva Abosch
Based on the success of deep brain stimulation (DBS) for treating movement disorders, there is growing interest in using DBS to treat schizophrenia (SZ). We review the unmet needs of patients with SZ and the scientific rationale behind the DBS targets proposed in the literature in order to guide future development of DBS to treat this vulnerable patient population. SZ remains a devastating disorder despite treatment. Relapse, untreated psychosis, intolerable side effects and the lack of effective treatment for negative and cognitive symptoms contribute to poor outcome...
December 14, 2017: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/29222987/frequency-and-correlates-of-tardive-dyskinesia-in-indian-patients-with-type-i-bipolar-disorder
#20
Tess Maria Rajan, Balaji Bharadwaj, Ravi Philip Rajkumar, Prashant Shankarrao Adole
BACKGROUND: Patients with Bipolar Disorder (BD) may have higher risk of Tardive Dyskinesia (TD). Theories for TD include inflammatory or oxidative stress and altered iron metabolism. The current frequency and clinical and biochemical correlates of TD in BD needs exploration. OBJECTIVES: To assess: (1) the frequency of TD in BD; (2) clinical correlates of TD in BD; (3) oxidative stress markers, inflammatory markers and hepcidin in TD in BD. MATERIALS & METHODS: In this cross-sectional study, 170 patients with BD were assessed for clinical characteristics using structured assessments...
December 5, 2017: Asian Journal of Psychiatry
keyword
keyword
112950
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"